Travere Therapeutics Provides Corporate Update and 2025 Outlook
13 janv. 2025 07h00 HE
|
Travere Therapeutics, Inc.
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA...
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual...
Travere Therapeutics to Present at Upcoming Investor Conferences
25 nov. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 nov. 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at Upcoming Investor Conferences
04 nov. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in...
Travere Therapeutics to Report Third Quarter 2024 Financial Results
21 oct. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the...
Travere Therapeutics to Present at Upcoming Investor Conferences
06 août 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:...
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 août 2024 16h01 HE
|
Travere Therapeutics, Inc.
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 mai 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics to Present at Upcoming Investor Conferences
08 mai 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA...